Media contact: Kira Gordon | kira@brightpointny.com | 646-243-4920
EndoStim Receives FDA Breakthrough Device Designation
EndoStim announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Company’s EndoStim System.
Read MoreEndoStim Appoints Eric B. Goorno as Chief Executive Officer
Goorno joins EndoStim to lead the company’s rebuilding through the regulatory approval, scale up and commercialization process.
Read MoreAbout Endostim
EndoStim is a medical device company developing and commercializing a first-in-class neurostimulation
treatment system for drug refractory gastroesophageal reflux disease (GERD). EndoStim therapy is designed to
restore normal esophageal function and preserve normal anatomy to avoid the typical gastrointestinal side
effects of traditional anti-reflux surgery. The EndoStim System has been successfully investigated in multiple
independent studies.